(JP2020512285) Glycopeptide antibiotics Construct 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(JP2020512285) Glycopeptide antibiotics Construct
公开号/公开日
JP2020512285 / 2020-04-23
申请号/申请日
JP2019530464 / 2017-12-11
发明人
Lansoni Andrea;
申请人
UNIV QUEENSLAND;
主分类号
IPC分类号
摘要
(JP2020512285) (i) Optionally derivatized glycopeptide antibiotics; (ii) nanoparticles; (i) and (iii) and (ii) connecting the first 1 linker constructs including the same are provided. The construct is present, the second 1 (ii) a linker positioned between the first 2 may further comprise a linker. Nanoparticles, such as magnetic separation for separating nanoparticles may be nanoparticles. Glycopeptide antibiotics, vancomycin; teicoplanin; oritavancin; telavancin; chloro-jer model clarithromycin; balhimycin selected from the group consisting of and may be. The constructs may be coupled with the bacteria is separated from the sample bacteria and method of, making and using the said constructs associated with the method are also provided.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
(JP2020512285) SHIMIZU, Hatsushi Reg. Nb: 100102978 Masao Haruna Reg. Nb: 100102118 Yukitaka Yamaguchi Reg. Nb: 100160923 Shinkenbun Reg. Nb: 100119507 INOE RYUICHI Reg. Nb: 100142929 SATO TOSHIMITSU Reg. Nb: 100148699 Koichi Shimome Reg. Nb: 100128048 KOBAYASHI TOMOHIKO Reg. Nb: 100129506 Hideo Kodera Reg. Nb: 100205707 Ozeki Masato Reg. Nb: 100114340 Igarashi Yoshihiro Reg. Nb: 100114889 Kazuya Kawamoto Reg. Nb: 100121072
代理机构
;
优先权号
2016AU-0905104
主权利要求
(JP2020512285) 1. (i) Optionally derivatized glycopeptide antibiotics; (ii) nanoparticles; (iii) and (i) 1 and (ii) a linker connecting the first, construct. 2. (Ii) the first 1 linker is located between the first and the linker further comprises a 2, a construct according to claim 1 of. 3. Separating nanoparticles and nanoparticles, preferably, with magnetic nano-particles are nano-particles for separation, comprising a construct of the claims 1 or 2. 4. A glycopeptide antibiotic, vancomycin; teicoplanin; oritavancin; telavancin; chloro-jer model clarithromycin; balhimycin and is selected from the group consisting, of any one of claims AAAGCCACCCAAGGCA. 5. Glycopeptide antibiotics vancomycin, a construct according to claim 4. 6. 1 The first linker is at least partially hydrophilic, one of the preceding claims wherein the construct. 7. 1 Is a hydrophobic linker of the first, the construct of any one of claims 1-5. 8. 1 A polyethylene glycol (PEG) linker of the first portion, a construct according to claim 6. 9. Preferably, PEG3 is a PEG moiety, a construct according to claim 8. 10. A first linker of 1, 4 comprises a straight chain of carbon greater than two, of the construct of any one of claims 6-8. 11. C8 Carbonitride is NLTK connection blocks, a construct according to claim 10. 11. 1 A third linker, C XhGREEK carboxy portion; N N primary or the secondary distal end portion; hydroxyl moiety; phenolic moieties; vancosamine and a moiety selected from the group consisting of a portion of the via, respectively connected to the glycopeptide antibiotic, wherein said construct of one of the preceding claims. 12. 1 A first via an amide bond linker coupled to a glycopeptide antibiotic, a construct according to claim 12. 13. 1 The first 1 linker of one or more of the nitrogen-containing moieties, and wherein the constructs of any one of claims. 14. 1 1 The second end of the linker molecule comprises a nitrogen-containing moiety, the linker portion is connected to the glycopeptide antibiotic, according to claim 13 construct. 15. 1 A linker of 2 molecule of the first end of the nitrogen-containing moieties, comprising the construct of the claims 13 or 14. 16. 1 An amine-containing moiety with a nitrogen derived from one or more of the portions and/or azide-derived moieties, of the construct of any one of claims 13-15. 17. 2 A linker of the first organic molecules, the construct of any one of claims 2-16. 18. 2 A first portion of the PEG linker, the construct of any one of claims 2-14. 19. PEG3 Is a PEG moiety, a construct according to claim 18. 20. 1 A first portion of the linker 2 via the first linker is derived from an azide coupled to, the construct of any one of claims 13-19. 21. 1 1 Is the linker of the first portion of the linker via a triazole linker coupled to a 2, a construct according to claim 20. 22. In which the protein or polymer nanoparticles construct has been passivated, and wherein the constructs of any one of claims. 23. A passivation, HSA; CMD; PDEC - dextran, and dextran is selected from the group consisting PDEA - due to the coating, a construct according to claim 22. 24. 1 Coating a first linker linked to the nanoparticle via, a construct according to claim 23. 25. 1 The first 2 linker is attached to the nanoparticle via a linker as coupled, the second 2 linker are attached to the coating, a construct according to claim 24. 26. A plurality of the glycopeptides antibiotic molecules, one of the preceding claims wherein the construct. 27. The moderate or high local density of a glycopeptide antibiotic having a molecular weight, according to claim 26 construct. 28. (i) Glycopeptide EXTRACTION optionally derivatized material; (ii) nanoparticles; 1 (iii) the first linker and the step of obtaining, (iii) and (ii) and (i) using a step of connecting, to produce a construct. 29. (a) (I) optionally derivatized glycopeptide antibiotics; (ii) nanoparticles; 1 (iii) the first linker; (iv) the first linker and the step of obtaining 2; (i) the (iii) (b) coupling the; (ii) the (c) coupling the (iv); (d) (iii) and (iv) coupling the comprising the steps of, to produce a construct. 30. (i) Optionally derivatized glycopeptide antibiotics; (ii) nanoparticles; and (iii) and (ii) (i) a linker connecting the first construct 1, to bind to the microorganism or a component thereof in the method, the microorganism or a component thereof (a) combining the construct step; PCIM (b) a glycopeptide antibiotic of the construct that selectively binds to a microorganism or component thereof by, or a component thereof in the microorganism the construct comprises the steps of binding, the method. 31. Using the construct, the microorganism is separated from the sample or a component thereof in the method, and optionally (ai), in the case where the sample is a blood sample, the step of aggregating blood cells; (a) optionally derivatized glycopeptide antibiotics; (ii) nanoparticles; (iii) and (i) 1 and (ii) a linker connecting the first construct comprising, in combination with the sample containing the microorganisms or components thereof comprising the step of; (b) the microorganism or a component thereof to construct a glycopeptide antibiotic binding selectively; (c) using the nanoparticles as well as, a microorganism or a component thereof from the sample bound to the construct obtained selectively, thereby, using a construct, is separated from the sample is a microorganism or component thereof comprising the steps of, wherein the method. 32. (A) a step where the sample, a biological sample obtained from a subject, the method according to claim 31. 33. The sample is urine, blood, blood or a blood preparation, according to claim 32 method. 34. In which the sample was obtained from a human, the method claims 32 or 33. 35. (A) a step in which the gram-positive bacterial microorganism, the method of any one of claims 30-34. 36. In which the pathogenic microorganism, the method according to claim 35. 37. (C) the step of, separating the magnetic nanoparticles is carried out using a magnetic capture of the nano-particles, the method of any one of claims 30-36. 38. The microorganism of interest in a sample for the presence of oil or a component thereof in a screening method, said method, and optionally (a) (i) a glycopeptide antibiotic derivatized; (ii) nanoparticles; (iii) and (i) 1 and (ii) a linker connecting the first construct, and the step of combining with the sample; (b) using the nanoparticles, the sample is selected from the construct in the step of obtaining; (c) a sequence of interest is a microorganism or a component thereof to determine whether the construct, or linked to determine whether or not the step in which, the microorganism or component thereof is of interest bound to the construct by determining the bound or, the sample containing the microorganisms of interest which have been shown to, the microorganism of interest construct or a component thereof not bonded or not is determined by, a microorganism of interest in a sample which does not contain oil or a component thereof is indicated, said method. 39. Microorganisms obtained from a sample to a method of analyzing or a component thereof, of any of (a) (i) a glycopeptide EXTRACTION derivatized; (ii) nanoparticles; and (iii) and (i) a linker connecting the first 1 (ii) a construct comprising, in combination with the sample containing the microorganisms or components thereof as step; microorganism or a component thereof (b) a glycopeptide antibiotic of a construct of the step of selectively binds; (c) using the nanoparticles, the microorganism or a component thereof from the sample bound to the construct to obtain selectively, thereby, the step of obtaining a microorganism or a component thereof from a sample; (d) optionally, a microbe or a component thereof is separated from a construct; (e) analyzing microorganisms as well as comprising the steps of, wherein the method. 40. (E) a step of analyzing comprises analysis by mass spectrometry MALDI, according to claim 39 method. 41. (E) the analysis of nucleic acid analysis step including the, method according to claim 39. 42. (E) analyzing the fluorescence analysis step including the, method according to claim 39. 43. Including a specific microbial analysis, the method of any one of claims 39-42. 44. (A) the construct of step, any one of claims 1-27 construct, according to any one of claims 28-43. 45. A disease, disorder, or a method of diagnosis of the state, in accordance with claim 43, in a biological sample obtained from a subject identifying a microorganism, in a subject on the basis of the identity of the microorganisms and the step of diagnosing the disease or condition comprising, method. 46. A disease, disorder, or a method of treatment of a condition, according to the method according to claim 45, disease, disorder, or condition in the diagnosing, based on the diagnosis comprising the steps of treating a disease or condition, the method. 47. To inhibit the microorganism, to control, kill or method, of any one of claims 1-27 constructs by contact with microorganisms, the microorganism to inhibit, control, or death comprising the step of, method. 48. A disease, disorder, or condition or for the prevention of, any one of claims 1-27 composition comprising the construct. 49. The disease in the subject, disorder, or condition in a method of treatment or prophylaxis, an effective amount of a construct according to any one of claims 1-27 according to claim 48 or by administering to the subject a composition of, the disease in the subject, disorder, or condition comprising the step of treating or preventing a, method. 50. A disease, disorder, or condition or in the manufacture of a composition for the prevention of, any one of claims 1-27 USED construct. 51. A glycopeptide antibiotic activity or increase the efficacy of the method, a glycopeptide antibiotic comprising the step of coupling the linker, and optionally, a glycopeptide antibiotic via a linker comprising the additional step of connecting the nanoparticles, the method. 52. C8 Or PEG3 comprises the linker, the method according to claim 51. 53. Bound to a linker, optionally derivatized glycopeptide antibiotics compound, a linker, at least a portion of the (i) PEG PEG3; (ii) at least 4 carbon atoms or comprising a straight chain comprising carbon, said compound.
法律状态
PENDING
专利类型码
A
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部